Semnur Pharmaceuticals: Semnur Pharmaceuticals, Inc. ("Semnur"), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, "Scilex"), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025

Semnur Pharmaceuticals: Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Semnur Pharmaceuticals: Semnur Pharmaceuticals to go public in $2bn SPAC deal

Semnur Pharmaceuticals: Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of

Semnur Pharmaceuticals: Sorrento Therapeutics Announces Merger of Scilex and Semnur

Semnur Pharmaceuticals: $SRNE Announces the Merger of Scilex and Semnur to Create a Global Leader in NonOpioid Pain Management httpsglobenewswire.comnewsrelease2019032217592380enSorrentoTherapeuticsAnnouncestheMergerofScilexandSemnurtoCreateaGlobalLeade

Semnur Pharmaceuticals: Semnur Pharmaceuticals Begins Pivotal Phase 3 Trial For SP-102 In Patients With Lumbar Radicular Pain/Sciatica